BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30666822)

  • 1. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy.
    Lee ES; Shin JM; Son S; Ko H; Um W; Song SH; Lee JA; Park JH
    Adv Healthc Mater; 2019 Feb; 8(4):e1801320. PubMed ID: 30666822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Engineering Cells for Cancer Immunotherapy.
    Xu X; Li T; Shen S; Wang J; Abdou P; Gu Z; Mo R
    Theranostics; 2019; 9(25):7889-7905. PubMed ID: 31695806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis.
    Zhang P; Zhai Y; Cai Y; Zhao Y; Li Y
    Adv Mater; 2019 Dec; 31(49):e1904156. PubMed ID: 31566275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.
    Lynn GM; Laga R; Jewell CM
    Cancer Lett; 2019 Sep; 459():192-203. PubMed ID: 31185250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
    Liu J; Zhang R; Xu ZP
    Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine for T-Cell Mediated Immunotherapy.
    Li F; Ouyang J; Chen Z; Zhou Z; Milon Essola J; Ali B; Wu X; Zhu M; Guo W; Liang XJ
    Adv Mater; 2024 May; 36(22):e2301770. PubMed ID: 36964936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
    Wei X; Wang J; Liang M; Song M
    Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
    de Charette M; Marabelle A; Houot R
    Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanovaccines for cancer immunotherapy.
    Zhang Y; Lin S; Wang XY; Zhu G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy.
    Li J; Luo Y; Pu K
    Angew Chem Int Ed Engl; 2021 Jun; 60(23):12682-12705. PubMed ID: 32671893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells in cancer immunotherapy.
    Gunzer M; Grabbe S
    Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinning molecular immunology into successful immunotherapy.
    Pardoll DM
    Nat Rev Immunol; 2002 Apr; 2(4):227-38. PubMed ID: 12001994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with dendritic cells as a cancer treatment: perspectives and therapeutic potential.
    Aleixo AA; Michelin MA; Murta EF
    Recent Pat Endocr Metab Immune Drug Discov; 2013 Sep; 7(3):226-32. PubMed ID: 23675964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of cancer immunotherapeutic strategies.
    Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
    Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
    Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.
    Joshi B; Wang X; Banerjee S; Tian H; Matzavinos A; Chaplain MA
    J Theor Biol; 2009 Aug; 259(4):820-7. PubMed ID: 19446568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in engineering local drug delivery systems for cancer immunotherapy.
    Abdou P; Wang Z; Chen Q; Chan A; Zhou DR; Gunadhi V; Gu Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1632. PubMed ID: 32255276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.